HCM
IRWD icon

Highbridge Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Highbridge Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-31,283
Closed -$393K – 1436
2017
Q4 		$393K Buy
+31,283
New +$409K 0.01% 1057

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Highbridge Capital Management's IRWD Position: Q4 2025 in Review

Highbridge Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2025, closing a stake of 537,252 shares — an estimated $704K sold.

Highbridge Capital Management first reported a position in IRWD in Q3 2013 and held it in 3 quarters. The position peaked at $5.14M in Q2 2015. 199 funds tracked by Wall St. Rank hold IRWD as of Q4 2025.

  • Highbridge Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Highbridge Capital Management sold 537,252 Ironwood Pharmaceuticals shares in Q4 2025, an estimated $704K.
  • Highbridge Capital Management first reported a position in Ironwood Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • Highbridge Capital Management's Ironwood Pharmaceuticals position peaked at $5.14M in Q2 2015.
  • 199 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2025.

Based on Highbridge Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.